SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid discussions about its financial performance and the ongoing release of Epstein-related documents. The community is expressing concerns about the company's future and the potential impact of these external factors, including political opinions and a mix of reactions, from staunch support to harsh criticism. Speculation is also circulating regarding potential market manipulation and the stock's long-term viability.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it dips below $100K, sparking discussions about potential support levels and the possibility of a larger correction. The crypto community is debating whether this is a buying opportunity or the start of a bear market, with some pointing to ETF flows and long-term holder behavior.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid a recent announcement of a $2.35 billion senior secured notes offering, leading to community debate around the company's debt strategy and its potential impact on growth. Community members are weighing the implications of this financial move against the backdrop of the AI sector's volatility, discussing whether this is a buying opportunity or a sign of deeper issues. Despite differing opinions, the company's existing contracts and long-term potential in the AI data center space remain central talking points.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a decision on its Alzheimer's treatment from the European Medicines Agency, with a hearing completed recently. Community discussions range from potential approval and short squeeze scenarios to concerns about data integrity and potential insider trading, fueled by commentary from controversial figures. The stock exhibits high volatility amidst speculation about the drug's prospects and impact on the broader Alzheimer's treatment landscape.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to lowered FY2025 revenue guidance, sparking concerns about short-term performance, while the community debates management and potential reverse splits. Despite the reduced outlook, long-term growth prospects related to defense and maritime contracts, along with analyst 'Strong Buy' ratings, are still being discussed, with some viewing the dip as a buying opportunity.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending downwards as investors express concerns about decreased revenue and profit, despite overall year-to-date growth. The community is debating whether recent facility upgrades and reliance on Dell will support future expansion and profitability, especially given lower numbers in recent earnings. Contrarian investors are hopeful for a bounce, citing a recent capital raise, while others express disappointment and question the company's communication strategy.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending amid speculation of a potential acquisition, with community members discussing rumors of a bidding war involving major pharmaceutical companies. The positive Phase 2 clinical data for their influenza candidate CD388 and a recent $339M BARDA award have increased optimism around the stock. Investors are closely watching for further developments, including potential price target updates and signals of a buyout.

Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending due to a mixed earnings report and weaker-than-expected guidance, sparking debate about its future growth prospects, particularly in China. The community is focused on whether the recent drop presents a buying opportunity or if it signals deeper challenges for the semiconductor equipment supplier. Discussions include the impact of potential tariffs and competition from other companies in the sector.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is trending due to recent FDA approval of their leukemia drug, KOMZIFTI, ahead of schedule, leading to community excitement around its potential market impact and improved safety profile compared to competitors. The community is actively discussing the implications of the approval, including potential milestone payments and the drug's advantages in dosing and safety, while also considering its competitive positioning against similar treatments. Despite some volatility and profit-taking, the approval is seen as a positive catalyst for the company's growth and potential acquisition.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss its potential for government backing and key developments from the latest earnings report. The community is focused on the CEO's trip to Washington D.C. and anticipation surrounding NOAA approval, with some highlighting the company's role in securing defense minerals amid geopolitical tensions.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nan Fung Trinity HK Ltd. Invests $5.90 Million in Akero Therapeutics, Inc. $AKRO

Nan Fung Trinity HK Ltd. purchased a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the...

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...

Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) Berger Montague PC...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...

<ul class="summary-bullets"><li>Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.</li><li>Some traders urged the company to pursue additional acquisitions, including Viking Therapeutics, while others highlighted upcoming catalysts such as the Wegovy pill and Alzheimer’s trials.</li><li>Novo reportedly viewed Metsera as a bolt-on deal rather than a transformational one and ultimately withdrew after Pfizer matched its latest offer amid rising valuation concerns and potential antitrust scrutiny.</li></ul>Novo Nordisk's retail traders showed resilience over the weekend after the Danish drugmaker lost a $10 billion bidding war for obesity-drug developer Metsera Inc. to Pfizer. Investors&nbsp;indicated that they remain confident in the company’s leadership, pipeline, and disciplined approach to dealmaking despite the setback.The stock finished lower in 13 of the past 14 sessions, with the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-snaps-11-day-losing-streak-after-court-rejects-pfizer-s-challenge-to-10-b-metsera-deal/cL2taIpREba">only uptick coming last week</a> after a Delaware judge briefly cleared the company’s bid for Metsera, rejecting Pfizer’s request to block the deal.<h2 class="st-heading-2">Retail Sentiment Holds Firm</h2>On Stocktwits, retail sentiment for Novo was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/140;" src="https://news.stocktwits-cdn.com/nvo_ss_jpg_422929e89b.webp" alt="nvo ss.jpg" width="969" height="140"><figcaption>NVO sentiment and message volume as of November 9 | Source: Stocktwits</figcaption></figure>Retail traders on Stocktwits maintained optimism about Novo’s outlook, with several saying they remained long on the stock and describing new CEO Mike Doustdar as “dynamic” and steering the company in the right direction. Some users said Novo was a “great buy” both before and after the Metsera outcome, while noting that patience would be needed as the company pursues its next phase of growth.<stembedurl>https://stocktwits.com/biolover/message/635540475</stembedurl><stembedurl>https://stocktwits.com/Rico_Again_Jorge/message/635526364</stembedurl>Others encouraged Novo to continue pursuing deals, urging it to “fight for your honor” and consider a potential bid for Viking Therapeutics. Some traders said they were unconcerned about the immediate market reaction, instead focusing on Novo’s longer-term potential, including its “great things in the pipeline” such as the Wegovy pill, a possible Alzheimer’s therapy, and other next-generation obesity treatments.<stembedurl>https://stocktwits.com/Magnificient/message/635525345</stembedurl><stembedurl>https://stocktwits.com/Europlus/message/635522144</stembedurl><h2 class="st-heading-2">Novo Refocuses After Metsera</h2>Novo CEO Mike Doustdar told executives in an internal email obtained by&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-08/novo-s-ceo-turns-to-next-targets-after-losing-metsera-to-pfizer">Bloomberg</a> that the company will now focus on its “own promising pipeline” while continuing to explore complementary business development opportunities in diabetes and obesity.Novo reportedly viewed Metsera as a bolt-on acquisition rather than a transformational one, and ultimately withdrew after Pfizer matched its latest offer amid rising valuation concerns and potential antitrust scrutiny.The company had also&nbsp;previously signaled&nbsp;that its business development strategy would prioritize deals with clear strategic alignment and financial discipline. Novo has already moved to expand its portfolio with a $5.2 billion purchase of Akero Therapeutics, developer of an experimental therapy for MASH, a liver disease linked to obesity.Novo has also filed for U.S. approval of a pill version of semaglutide, the active ingredient in Wegovy and Ozempic, and is studying the drug’s potential in mild Alzheimer’s disease.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s stock</a> has declined 46% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Equity

Akero Therapeutics (NASDAQ:AKRO) Releases Quarterly Earnings Results

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of...

Akero Therapeutics (AKRO) Projected to Post Earnings on Friday

Akero Therapeutics (NASDAQ:AKRO) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...

Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders PR...

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Akero Therapeutics Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

Current Price	$54.20
Prev Close	$54.30
Open	$54.25
Dividend Yield	0.00%
50-Day Moving Average	$49.71
Beta	0.94
Avg. Volume	3.77M
PE Ratio	-14.49

52-Week High	$58.40
52-Week Low	$21.34
Market Capitalization	$4.47B
EPS (Annual)	-$3.75
Price to Book	4.54
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AKRO
Akero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKRO News

AKROAkero Therapeutics Inc